X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs CADILA HEALTHCARE - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD CADILA HEALTHCARE ALEMBIC LTD/
CADILA HEALTHCARE
 
P/E (TTM) x 51.7 18.8 274.7% View Chart
P/BV x 2.2 4.5 48.4% View Chart
Dividend Yield % 0.5 0.9 51.4%  

Financials

 ALEMBIC LTD   CADILA HEALTHCARE
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
CADILA HEALTHCARE
Mar-18
ALEMBIC LTD/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs72558 12.9%   
Low Rs34362 9.4%   
Sales per share (Unadj.) Rs4.7116.3 4.0%  
Earnings per share (Unadj.) Rs6.117.9 34.2%  
Cash flow per share (Unadj.) Rs6.223.1 27.0%  
Dividends per share (Unadj.) Rs0.203.50 5.7%  
Dividend yield (eoy) %0.40.8 49.6%  
Book value per share (Unadj.) Rs40.785.4 47.6%  
Shares outstanding (eoy) m267.031,023.74 26.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.34.0 284.9%   
Avg P/E ratio x8.725.7 33.7%  
P/CF ratio (eoy) x8.519.9 42.7%  
Price / Book Value ratio x1.35.4 24.2%  
Dividend payout %3.319.6 16.7%   
Avg Mkt Cap Rs m14,139470,664 3.0%   
No. of employees `000NA11.8 0.0%   
Total wages/salary Rs m20718,545 1.1%   
Avg. sales/employee Rs ThNM10,072.7-  
Avg. wages/employee Rs ThNM1,569.1-  
Avg. net profit/employee Rs ThNM1,547.7-  
INCOME DATA
Net Sales Rs m1,255119,049 1.1%  
Other income Rs m3701,132 32.7%   
Total revenues Rs m1,625120,181 1.4%   
Gross profit Rs m11128,475 0.4%  
Depreciation Rs m385,388 0.7%   
Interest Rs m2911 0.2%   
Profit before tax Rs m44223,308 1.9%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m245,644 0.4%   
Profit after tax Rs m1,63018,292 8.9%  
Gross profit margin %8.923.9 37.0%  
Effective tax rate %5.424.2 22.4%   
Net profit margin %129.815.4 845.1%  
BALANCE SHEET DATA
Current assets Rs m1,86782,005 2.3%   
Current liabilities Rs m59160,720 1.0%   
Net working cap to sales %101.617.9 568.5%  
Current ratio x3.21.4 233.8%  
Inventory Days Days9473 128.9%  
Debtors Days Days7498 74.8%  
Net fixed assets Rs m1,79183,703 2.1%   
Share capital Rs m5341,024 52.2%   
"Free" reserves Rs m10,32486,421 11.9%   
Net worth Rs m10,85887,445 12.4%   
Long term debt Rs m4125,551 0.2%   
Total assets Rs m11,591180,653 6.4%  
Interest coverage x260.926.6 981.3%   
Debt to equity ratio x00.3 1.3%  
Sales to assets ratio x0.10.7 16.4%   
Return on assets %14.110.6 132.4%  
Return on equity %15.020.9 71.8%  
Return on capital %15.222.0 69.1%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1942,683 0.0%   
Fx outflow Rs m26411,242 2.3%   
Net fx Rs m-24431,441 -0.8%   
CASH FLOW
From Operations Rs m2369,193 2.6%  
From Investments Rs m-224-9,737 2.3%  
From Financial Activity Rs m-27515 -5.2%  
Net Cashflow Rs m-15-29 51.0%  

Share Holding

Indian Promoters % 64.0 74.8 85.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 8.3 2.4%  
FIIs % 9.7 5.9 164.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 11.0 237.3%  
Shareholders   54,701 44,069 124.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  FULFORD INDIA  MERCK LTD  

Compare ALEMBIC LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 297 Points Higher; Energy and Realty Stocks Witness Buying(Closing)

Share markets in India continued their momentum during closing hours and ended the day on a positive note. Sectoral indices were trading on a positive note, with stocks in the energy sector.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)

Oct 3, 2018

A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.

Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)

Oct 3, 2018

Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Oct 16, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 8-QTR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS